Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...
AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...
AbbVie Inc. (NYSE:ABBV) is one of the best performing pharma stocks in 2025. AbbVie Inc. (NYSE:ABBV) was downgraded to Peer ...
On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an ...
AbbVie’s ABBV key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing ...
AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...
The last time I wrote about AbbVie (ABBV) was with respect to a Seeking Alpha article entitled "AbbVie: Skyrizi And Rinvoq Latest FDA Approvals Bode Well For Humira Patent Loss". With this respect to ...
AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...
AbbVie ABBV announced positive top-line results from a late-stage study, U-EXCEED, on Rinvoq (upadacitinib), a selective and reversible JAK inhibitor. AbbVie’s study enrolled patients with moderate-to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback